Emelyanov Andrey O, Sechko Elena, Koksharova Ekaterina, Sklyanik Igor, Kuraeva Tamara, Mayorov Alexander, Peterkova Valentina, Dedov Ivan
Endocrinology Research Centre, Moscow, Russian Federation.
Endocrinology Research Centre, Moscow, Russian Federation; I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation.
Int Med Case Rep J. 2017 Mar 7;10:77-80. doi: 10.2147/IMCRJ.S125103. eCollection 2017.
We report the case of a 12-year-old boy with a glucokinase () mutation, and diabetes with hyperinsulinemia and insulin resistance. For 4 years, the patient intermittently received insulin medications Actrapid HM and Protaphane HM (total dose 5 U/day), with glycated hemoglobin (HbA) levels of 6.6%-7.0%. After extensive screening the patient was found to carry a heterozygous mutation (p.E256K) in (MIM #138079, reference sequence NM_000162.3). Insulin therapy was replaced by metformin at 1,700 mg/day. One year later, his HbA level was 6.9%, postprandial glycemia at 120 min of oral glucose tolerance test was 15.4 mmol/L, hyperinsulinemia had increased to 508.9 mU/L, homeostasis model assessment index was 114.2 and the Matsuda index was 0.15. Insulin resistance was confirmed by a hyperinsulinemic euglycemic clamp test - M-index was 2.85 mg/kg/min. This observation is a rare case of one of the clinical variants of diabetes, which should be taken into account by a vigilant endocrinologist due to the need for nonstandard diagnostic and therapeutic approaches.
我们报告了一例12岁男孩的病例,该男孩存在葡萄糖激酶()突变,患有高胰岛素血症和胰岛素抵抗的糖尿病。4年来,该患者间歇性接受胰岛素药物Actrapid HM和Protaphane HM(总剂量5 U/天)治疗,糖化血红蛋白(HbA)水平为6.6%-7.0%。经过广泛筛查,发现该患者携带(MIM #138079,参考序列NM_000162.3)的杂合突变(p.E256K)。胰岛素治疗被替换为二甲双胍,剂量为1700 mg/天。一年后,他的HbA水平为6.9%,口服葡萄糖耐量试验120分钟时的餐后血糖为15.4 mmol/L,高胰岛素血症增加至508.9 mU/L,稳态模型评估指数为114.2,松田指数为0.15。通过高胰岛素正常血糖钳夹试验证实存在胰岛素抵抗——M指数为2.85 mg/kg/min。该观察结果是糖尿病临床变异型中的罕见病例,警惕的内分泌科医生应予以考虑,因为需要采用非标准的诊断和治疗方法。